thromboxane b2

Summary

Summary: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).

Top Publications

  1. ncbi Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    F Catella-Lawson
    EUPENN Group of Investigators, Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia 19104-6084, USA
    N Engl J Med 345:1809-17. 2001
  2. pmc Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase
    R M McMillan
    ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire
    Br J Pharmacol 107:1042-7. 1992
  3. pmc Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction
    J P De La Cruz
    Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, 29071 Malaga, Spain
    Br J Pharmacol 137:1082-8. 2002
  4. ncbi Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine
    Garrett J Gross
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisc 53226 3548, USA
    Pharmacology 71:135-42. 2004
  5. ncbi Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease
    Zhengyuan Xia
    Department of Anesthesiology, Affiliated Renmin Hospital, Wuhan University, PR China
    J Thorac Cardiovasc Surg 126:1404-10. 2003
  6. ncbi Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
    Rocio Gonzalez-Conejero
    University of Murcia, Centro Regional de Hemodonacion, Ronda de Garay S N, 30003, Murcia, Spain
    Stroke 36:276-80. 2005
  7. ncbi 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils
    Eva Böhm
    Department of Experimental and Clinical Pharmacology, Medical University Graz, A 8010 Graz, Austria
    J Biol Chem 279:7663-70. 2004
  8. ncbi In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production
    M Cattaneo
    A Bianchi Bonomi Hemophilia and Thrombosis Center, I R C C S Maggiore Hospital, Italy
    Thromb Res 62:717-24. 1991
  9. ncbi Variations in white blood count, thromboxane B2 levels and hematocrit in chronic venous hypertension
    P C Guimarães
    Vascular Surgery Service, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil
    Sao Paulo Med J 116:1721-6. 1998
  10. ncbi Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus
    Wendy I Baltzer
    Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A and M University, College Station, TX 77843 4474, USA
    Am J Vet Res 67:78-83. 2006

Detail Information

Publications194 found, 100 shown here

  1. ncbi Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    F Catella-Lawson
    EUPENN Group of Investigators, Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia 19104-6084, USA
    N Engl J Med 345:1809-17. 2001
    ..Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin...
  2. pmc Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase
    R M McMillan
    ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire
    Br J Pharmacol 107:1042-7. 1992
    ..In human and dog blood, ICI D2138 did not inhibit thromboxane B2 synthesis at a concentration of 500 microM, thus the selectivity ratio (cyclo-oxygenase: 5-lipoxygenase) was ..
  3. pmc Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction
    J P De La Cruz
    Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, 29071 Malaga, Spain
    Br J Pharmacol 137:1082-8. 2002
    ..4. In conclusion, the effect of specific blockage of TxS together with blockage of membrane receptors for TxA(2) can surpass the effect of ASA in inhibiting the platelet-subendothelium interaction in flow conditions...
  4. ncbi Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine
    Garrett J Gross
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisc 53226 3548, USA
    Pharmacology 71:135-42. 2004
    ..to establish inhibition of COX-2 (lipopolysaccharide-stimulated prostaglandin E2 formation) and COX-1 (serum thromboxane B2) in blood taken from dogs administered 1, 3, or 10 mg/kg naproxen or 15 mg/kg SC-58236...
  5. ncbi Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease
    Zhengyuan Xia
    Department of Anesthesiology, Affiliated Renmin Hospital, Wuhan University, PR China
    J Thorac Cardiovasc Surg 126:1404-10. 2003
    ..The relationship between endothelin-1 and the endothelium-derived prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also investigated...
  6. ncbi Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
    Rocio Gonzalez-Conejero
    University of Murcia, Centro Regional de Hemodonacion, Ronda de Garay S N, 30003, Murcia, Spain
    Stroke 36:276-80. 2005
    ..The widespread use of aspirin requires clarification of the aspirin resistance phenomenon. Most studies on this field are focused on patients which may affect the action of aspirin...
  7. ncbi 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils
    Eva Böhm
    Department of Experimental and Clinical Pharmacology, Medical University Graz, A 8010 Graz, Austria
    J Biol Chem 279:7663-70. 2004
    ..Given its production in the allergic lung, antagonism of the 11-dehydro-TXB(2)/CRTH2axis may be of therapeutic relevance...
  8. ncbi In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production
    M Cattaneo
    A Bianchi Bonomi Hemophilia and Thrombosis Center, I R C C S Maggiore Hospital, Italy
    Thromb Res 62:717-24. 1991
    ..3 picolyl-4-methoxy-isophthalamide) on human platelet aggregation, the release reaction and the production of thromboxane B2 (TxB2) induced by several platelet agonists...
  9. ncbi Variations in white blood count, thromboxane B2 levels and hematocrit in chronic venous hypertension
    P C Guimarães
    Vascular Surgery Service, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil
    Sao Paulo Med J 116:1721-6. 1998
    To analyze variations in leukocyte count and thromboxane B2 production in the femoral vein of patients with chronic venous hypertension (CVH).
  10. ncbi Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus
    Wendy I Baltzer
    Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A and M University, College Station, TX 77843 4474, USA
    Am J Vet Res 67:78-83. 2006
    To measure 11-dehydro-thromboxane B2 (11-dTXB2) in urine of healthy control dogs, dogs undergoing ovariohysterectomy, and dogs with gastric dilatation-volvulus (GDV) and assess the relationship between urinary 11-dTXB2 concentrations in ..
  11. ncbi Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics
    M Kumlin
    Department of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden
    Am Rev Respir Dis 146:96-103. 1992
    ..abstract truncated at 250 words)..
  12. doi Validation of immunoassays for the candidate renal markers C-reactive protein, immunoglobulin G, thromboxane B2 and retinol binding protein in canine urine
    Bert E J Maddens
    Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
    Vet Immunol Immunopathol 134:259-64. 2010
    ....
  13. ncbi Variable platelet response to aspirin and clopidogrel in atherothrombotic disease
    Andrew O Maree
    Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Boston, Mass, USA
    Circulation 115:2196-207. 2007
  14. ncbi Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma
    George G Chen
    Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Shatin, Hong Kong
    Cancer Lett 234:193-8. 2006
    ..In conclusion, our study demonstrates that the production of TXB(2) is increased in lung tumor tissues and that such an increase can result in lipid peroxidation which may be met by an elevation in Bcl-2 expression...
  15. ncbi Changes in crevicular fluid levels of interleukin-1 beta, leukotriene B4, prostaglandin E2, thromboxane B2 and tumour necrosis factor alpha in experimental gingivitis in humans
    P A Heasman
    Dental School, University of Newcastle upon Tyne, England
    J Periodontal Res 28:241-7. 1993
    ..Crevicular fluid samples were assayed in quadruplicate for prostaglandin E2 (PGE2), thromboxane B2 (TxB2), leukotriene B4, interleukin-1 beta (IL-1 beta) and tumour necrosis factor alpha (TNF alpha) by RIAs or ..
  16. ncbi Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance
    Andrew L Frelinger
    Center for Platelet Function Studies, Department of Pediatrics, UMass Memorial Medical Center, 55 Lake Ave N, Worcester, Massachusetts 01655, USA
    Circulation 113:2888-96. 2006
    ..Thrombotic events still occur in aspirin-treated patients with coronary artery disease...
  17. ncbi Platelet activation in obese women: role of inflammation and oxidant stress
    Giovanni Davi
    Center of Excellence on Aging, G D Annunzio University Schools of Medicine and Pharmacy, Chieti, Italy
    JAMA 288:2008-14. 2002
    ..Obesity, in particular abdominal adiposity, is associated with increased cardiovascular morbidity and mortality through mechanisms possibly linking the metabolic disorder to platelet and vascular abnormalities...
  18. ncbi Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways
    Tsutomu Michibayashi
    Clinical Pathophysiology, Division of Human Comprehensive Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    J Atheroscler Thromb 12:154-62. 2005
    ..Thus, it may be concluded that PAF-induced platelet aggregation participates in activation of the 12-LOX pathway and is accompanied by the release of vasodepressor nerve-stimulating substances from platelets...
  19. ncbi Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo
    Jochen Graff
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology at the Johann Wolfgang Goethe University Frankfurt, Germany
    J Antimicrob Chemother 61:394-9. 2008
    ..Recently, the FDA published a warning concerning intracranial haemorrhage in patients taking the HIV-1 protease inhibitor tipranavir co-administered with ritonavir...
  20. ncbi Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    John W Eikelboom
    Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
    Circulation 105:1650-5. 2002
    ..We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population...
  21. ncbi Aspirin resistance: definition, mechanisms and clinical read-outs
    C Patrono
    University of Rome La Sapienza, Rome, Italy
    J Thromb Haemost 1:1710-3. 2003
  22. ncbi Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay
    M Feldman
    Medical Service, Dallas Department of Veterans Affairs Medical Center, Texas 75216, USA
    J Am Coll Cardiol 37:2036-41. 2001
    ..We performed a placebo-controlled study to evaluate the effect of low-dose aspirin on serum C-reactive protein (CRP) levels...
  23. ncbi Aspirin resistance
    Jorge Rouvier
    Circulation 106:e200-1; author reply e200-1. 2002
  24. ncbi Seasonal variation in parameters related to coronary heart disease risk in young men
    V Mustad
    Graduate Program in Nutrition, Pennsylvania State University, University Park 16802, USA
    Atherosclerosis 126:117-29. 1996
    ..An understanding of these variations is important not oly for clinical evaluation and metabolic study design issues, but more importantly, to clarify their clinical significance with the seasonal incidence of CHD events...
  25. ncbi Effect of modified ultrafiltration on plasma thromboxane B2, leukotriene B4, and endothelin-1 in infants undergoing cardiopulmonary bypass
    J M Pearl
    Division of Pediatric Cardiothoracic Surgery, Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Ann Thorac Surg 68:1369-75. 1999
    Plasma thromboxane B2 (TXB2), leukotriene B4 (LTB4), and endothelin-1 (ET-1) levels increase on cardiopulmonary bypass (CPB)...
  26. ncbi Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population
    Nauder Faraday
    Division of Cardiac Surgical Intensive Care, Department of Anesthesiology Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Am J Cardiol 98:774-9. 2006
    ..aspirin resistance on several different platelet function assays, including the level of urinary 11-dehydro thromboxane B2 (Tx-M), platelet aggregation to arachidonic acid and adenosine diphosphate, and closure time on the platelet ..
  27. ncbi Can platelet function tests predict the clinical efficacy of aspirin?
    Hannelore Haubelt
    Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, Ludwigshafen, Germany
    Semin Thromb Hemost 31:404-10. 2005
    ..Recent data demonstrate that none of the currently developed assays, including the PFA-100 system, are presently able to accomplish these objectives...
  28. ncbi Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 60:653-63. 2001
    ..We also examined the combination of MMF with a selective cyclooxygenase-2 (COX-2) inhibitor, DFU, based on previous findings of excessive renal production of COX-2-derived thromboxane A2 (TXA2) in lupus nephritis...
  29. ncbi Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia
    Li Ping Ma
    Department of Internal Medicine, Sun Yat Sen Memorial Hospital, Sun Yat Sen University of Medical Sciences, Guangzhou, People s Republic of China
    J Assoc Acad Minor Phys 13:23-6. 2002
    ..01), (2) ADP-induced maximum platelet aggregation (P < 0.01), (3) TXB2 or thromboxane B2 in platelets (P < 0.01), and (4) expression of GMP-140 or granule membrane protein-140 (P < 0.01)...
  30. ncbi Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease
    Andrew O Maree
    Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland
    J Am Coll Cardiol 46:1258-63. 2005
    ..We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals...
  31. ncbi Platelet activating factor and thromboxane B2 production after cardiopulmonary bypass
    D M Ansley
    Department of Anesthesia and Surgery, Vancouver Hospital, British Columbia, Canada
    J Invest Surg 10:87-95. 1997
    ..The purpose of this study was to investigate the relationships among production of PAF, thromboxane B2 (T alpha B2), and cardiopulmonary sequelae in patients undergoing coronary artery bypass graft surgery (CABGS)...
  32. ncbi Propofol has both enhancing and suppressing effects on human platelet aggregation in vitro
    H Hirakata
    Department of Anesthesia, Kyoto University Hospital, Japan
    Anesthesiology 91:1361-9. 1999
    ..In contrast, there is conflicting information regarding the effect of propofol on platelet function. The present study was designed to clarify the effects of propofol on platelet function and the mechanisms underlying these effects...
  33. ncbi Escherichia coli lipopolysaccharide potentiation and inhibition of rat neonatal microglia superoxide anion generation: correlation with prior lactic dehydrogenase, nitric oxide, tumor necrosis factor-alpha, thromboxane B2, and metalloprotease release
    A M Mayer
    Midwestern University, Chicago College of Osteopathic Medicine, Department of Pharmacology, Downers Grove, Illinois 60515, USA
    Shock 11:180-6. 1999
    ..O2- generation; 3-10 ng/mL LPS caused nitric oxide, tumor necrosis factor-alpha (TNF-alpha), thromboxane B2 and matrix metalloproteinase-9 release although partially inhibiting ensuing phorbol-12 myristate 13-acetate-..
  34. ncbi Ibuprofen therapy in experimental porcine gram-negative septic shock
    M P Griffin
    Department of Pediatrics, University of Texas Medical Branch, Galveston
    Resuscitation 22:75-83. 1991
    ..4 h in the benzyl alcohol group and 15.7 +/- 2.7 h in the animals receiving lactated Ringer's solution. Thromboxane B2 levels were not significantly different in the treatment vs...
  35. ncbi Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders
    Merja Vainio
    Department of Obstetrics and Gynecology, Hyvinkaa Hospital, Hyvinkaa, Finland
    Acta Obstet Gynecol Scand 83:1119-23. 2004
    ..The aim of this study was to investigate the prostanoid production in pregnancies at high risk for hypertensive disorders, and the effect of low-dose acetylsalicylic acid (ASA) on prostanoids...
  36. ncbi p-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo
    Cristina Luceri
    Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
    Br J Nutr 97:458-63. 2007
    ..in plasma antioxidant activity, measured as ferric reducing ability of plasma, and with the reduction of thromboxane B2 production...
  37. pmc Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
    N P Dowd
    Department of Anaesthesia and Intensive Care, Beaumont Hospital, Dublin, Ireland
    J Clin Invest 108:585-90. 2001
    ..In contrast, administration of a COX-1 inhibitor SC560 at a dose that reduced serum thromboxane B2 by more than 80% did not prevent the doxorubicin-induced increase in prostacyclin generation...
  38. ncbi D-003, a potential antithrombotic compound isolated from sugar cane wax with effects on arachidonic acid metabolites
    V Molina
    Center of Natural Products, National Center for Scientific Research, Cubanacan, Havana, Cuba
    Prostaglandins Leukot Essent Fatty Acids 67:19-24. 2002
    ..The present results support that these effects of D-003 on AA metabolites could explain, at least partially, its antiplatelet and antithrombotic effects...
  39. ncbi Modulation of platelet aggregation by areca nut and betel leaf ingredients: roles of reactive oxygen species and cyclooxygenase
    Jiiang Huei Jeng
    Laboratory of Dental Pharmacology and Toxicology, Graduate Institute of Clinical Dental Science, National Taiwan University, Taipei, Taiwan
    Free Radic Biol Med 32:860-71. 2002
    ..AN extract (1 and 2 mg/ml) stimulated rabbit platelet aggregation, with induction of thromboxane B2 (TXB2) production...
  40. ncbi Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers
    Keith D Wilner
    Pfizer Global Research and Development, San Diego, California 92122, USA
    J Clin Pharmacol 42:1027-30. 2002
    ..Therefore, these data indicate that celecoxib does not alter the effects of aspirin on platelet function...
  41. ncbi Effects of enteric-coated, low-dose aspirin on parameters of platelet function
    A Van Hecken
    Center for Clinical Pharmacology, University Hospital Gasthuisberg, Leuven, Belgium
    Aliment Pharmacol Ther 16:1683-8. 2002
    ..Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents...
  42. ncbi Drug insight: aspirin resistance-fact or fashion?
    Andrew O Maree
    Nat Clin Pract Cardiovasc Med 4:E1; author reply E2. 2007
  43. ncbi Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis
    T Watanabe
    Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
    Thromb Res 104:77-83. 2001
    ..The increase in sensitivity of the platelets to prostacyclin could be a compensatory mechanism against a decrease in the prostanoid production, presumably associated with endothelial dysfunction...
  44. ncbi Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin
    S Guthikonda
    Department of Cardiology, Emory University, Atlanta, GA 77030, USA
    J Thromb Haemost 5:490-6. 2007
    ..The mechanisms for the variability in antiplatelet effects of aspirin are unclear. Immature (reticulated) platelets may modulate the antiplatelet effects of aspirin through uninhibited cyclooxygenase (COX)-1 and COX-2...
  45. ncbi Anti-platelet and anti-thrombotic effects of triacetylshikimic acid in rats
    Fengyang Huang
    Pharmacobiology Department, Cinvestav I P N, Mexico City, Mexico
    J Cardiovasc Pharmacol 39:262-70. 2002
    ..Also, no significant changes in ADP-induced thromboxane B2 formation in rat platelets or 6-keto-prostaglandin F 1alpha production from the abdominal aorta were observed ..
  46. ncbi 1A-779 attenuates angiotensin-(1-7) depressor response in salt-induced hypertensive rats
    Mohamed A Bayorh
    Department of Pharmacology and Toxicology, Morehouse School of Medicine, 720 Westview Drive, S W, Atlanta, GA 30310 1495, USA
    Peptides 23:57-64. 2002
    ....
  47. ncbi Genetic variation in cyclooxygenase 1: effects on response to aspirin
    Marc K Halushka
    Department of Genetics and Center for Human Genetics, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, USA
    Clin Pharmacol Ther 73:122-30. 2003
    ..Cyclooxygenase 1 (prostaglandin endoperoxide G/H synthase [PTGS1]) catalyzes the metabolism of arachidonic acid to prostaglandin H(2), which is subsequently metabolized to thromboxane A(2)...
  48. ncbi Moderation of the platelet releasate response by aspirin
    Judith A Coppinger
    Department of Cell Biology, Scripps Research Institute, La Jolla, CA, USA
    Blood 109:4786-92. 2007
    ..These observations were confirmed for several cytokines using an antibody array approach...
  49. ncbi Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood
    J A Gonzalez-Correa
    Department of Pharmacology and Therapeutics, School of Medecine, University of Malaga, Campus de Teatinos s n, Malaga, Spain
    Platelets 16:171-9. 2005
    ..plasma (PRP) with ADP, collagen or arachidonic acid as platelet inducers, and we measured the production of thromboxane B2, prostacyclin and nitric oxide...
  50. ncbi Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats
    Marie Eve Rodrigue
    Research Centre and Division of Nephrology, CHUQ, L Hôtel Dieu de Québec Hospital and Department of Medicine, Laval University, Quebec, Canada
    Can J Physiol Pharmacol 83:467-75. 2005
    ..These results stress the importance of preserving PGI2 production when treating rhEPO-induced hypertension under uremic conditions...
  51. ncbi Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)
    Teresa Corazzi
    Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Via Enrico Dal Pozzo, 06126, Perugia, Italy
    J Pharmacol Exp Ther 315:1331-7. 2005
    ....
  52. ncbi Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers
    E Munsterhjelm
    Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, Finland
    Br J Anaesth 97:226-31. 2006
    ..The authors studied the effect of a combination of i.v. parecoxib and acetaminophen on platelet function in healthy volunteers...
  53. ncbi Effects of DK-002, a synthesized (6aS,cis)-9,10-Dimethoxy-7,11b-dihydro-indeno[2,1-c]chromene-3,6a-diol, on platelet activity
    Ki Seon Lee
    Department of Preventive Pharmacy, College of Pharmacy, Seoul National University, Seoul 151 742, Korea
    Life Sci 78:1091-7. 2006
    ....
  54. ncbi Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production
    Jiiang Huei Jeng
    Laboratory of Dental Pharmacology and Toxicology, Department of Dentistry, National Taiwan University Hospital and National Taiwan University, College of Medicine, Taipei, Taiwan
    Atherosclerosis 191:250-8. 2007
    ..Sanguinarine may have therapeutic potential for treatment of cardiovascular diseases related to platelet aggregation...
  55. ncbi Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects
    J Jermany
    Exploratory Clinical Development, Novartis Pharma AG, WSJ 103 4 D, CH 4002 Basel, Switzerland
    J Clin Pharmacol 45:1172-8. 2005
    ..Urinary thromboxane and prostacyclin were unaffected by lumiracoxib. In conclusion, concomitant lumiracoxib did not interfere with the cyclooxygenase-1-mediated antiplatelet effects of low-dose aspirin...
  56. ncbi 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets
    Chin Chung Wu
    Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan
    Eur J Pharmacol 527:37-43. 2005
    ..In a parallel manner, both arachidonic acid-induced thromboxane B2 and prostaglandin D2 formations were decreased in platelets treated with HPW-RX2...
  57. ncbi [Effect of phenolic alkaloids of Menispermum dauricum on thrombosis and platelet aggregation]
    Xiang Ying Kong
    Department of Pharmacology, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China
    Yao Xue Xue Bao 40:916-9. 2005
    ..To observe the effect of phenolic alkaloids of Menispermum dauricum (PAMD) on thrombosis and platelet aggregation, and to explore its mechanism of action...
  58. ncbi Human pharmacology of naproxen sodium
    Marta L Capone
    Department of Medicine and Center of Excellence on Aging, School of Medicine, G D Annunzio University, Chieti, Italy
    J Pharmacol Exp Ther 322:453-60. 2007
    ..In conclusion, neither of the two naproxen doses mimed the persistent and complete inhibition of platelet COX-1 activity obtained by aspirin, but marked heterogeneity was mitigated by the higher dose of the drug...
  59. ncbi Dose- and time-dependent antiplatelet effects of aspirin
    Christina Perneby
    Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital Solna, SE 171 76 Stockholm, Sweden
    Thromb Haemost 95:652-8. 2006
    ..5 mg aspirin daily, as evidenced by >98% suppression of serum thromboxane B2 and almost abolished arachidonic acid (AA) induced aggregation in PRP 2-6 h after dosing...
  60. ncbi Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients
    T Ohmori
    Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
    J Thromb Haemost 4:1271-8. 2006
    ..In this study, we examined individual thromboxane biosynthesis and platelet aggregation in aspirin-treated patients, and whether the results of a platelet aggregation test influenced clinical outcomes...
  61. ncbi Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease
    Maria G Sciulli
    Department of Medicine and Center of Excellence on Aging, G D Annunzio University, School of Medicine Gabriele d Annunzio University Foundation, Chieti, Italy
    Clin Pharmacol Ther 80:115-25. 2006
    ....
  62. ncbi Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro
    E Munsterhjelm
    Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, Finland
    Acta Anaesthesiol Scand 49:840-6. 2005
    ..Clinically paracetamol is often used together with traditional NSAIDs, which are strong inhibitors of COX. We studied binding of paracetamol to COX and its action on platelet function together with diclofenac...
  63. ncbi Synergistic effect of D-003 and aspirin on experimental thrombosis models
    V Molina
    Center of Natural Products, National Center for Scientific Research, Ave 25 and 158, Cubanacan, Havana 6880, Cuba
    Prostaglandins Leukot Essent Fatty Acids 68:305-10. 2003
    ..D-003 and ASA monotherapies reduced serum TxB(2) levels, whereas D-003, but not ASA, significantly increased 6 keto PgF1alpha levels...
  64. ncbi Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men
    Ewa Tuleja
    Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland
    Arterioscler Thromb Vasc Biol 23:1111-5. 2003
    ..We tested the hypothesis that naproxen, contrary to rofecoxib, exerts antithrombotic effects...
  65. ncbi The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial
    Philip T Leese
    Quintiles Phase I Services, Lenexa, Kansas, USA
    J Clin Pharmacol 43:504-13. 2003
    ..Platelet aggregation (to sodium arachidonate, collagen, and adenosine diphosphate), bleeding time, and serum thromboxane B2 (TxB2) concentrations were measured up to 8 hours postdose on Days 1 and 8...
  66. ncbi Dual inhibition of cyclooxygenase and lipoxygenase by human haptoglobin: its polymorphism and relation to hemoglobin binding
    Sheikh Arshad Saeed
    Dr Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan
    Biochem Biophys Res Commun 353:915-20. 2007
    ..This indicates that mammals have dual defense system, i.e., a specific immune system and non-specific Hp defense system...
  67. ncbi In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis
    María Monsalud Arrebola
    Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, Malaga, Spain
    J Cardiovasc Pharmacol 43:74-82. 2004
    ..All three drugs impaired the platelet-subendothelium interaction under flow conditions. With thienopyridines, the presence of endothelium did not modify the percentage of the surface coated by platelets...
  68. ncbi Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
    Marta L Capone
    Department of Medicine and Center of Excellence on Aging, G D Annunzio University, School of Medicine, and G d Annunzio University Foundation, Chieti, Italy
    Circulation 109:1468-71. 2004
    ..The current controversy on the potential cardioprotective effect of naproxen prompted us to evaluate the extent and duration of platelet, monocyte, and vascular cyclooxygenase (COX) inhibition by naproxen compared with low-dose aspirin...
  69. ncbi Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation
    Serenella Rotondo
    Laboratory of Vascular Biology and Pharmacology, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    Eur J Pharmacol 488:79-83. 2004
    ..These results indicate that, at clinically relevant concentrations, licofelone exerts a potent antiplatelet effect mediated by the inhibition of cyclooxygenase-1 activity...
  70. ncbi Inhibition of platelet aggregation by polyaspartoyl L-arginine and its mechanism
    Yin ye Wang
    Department of Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China
    Acta Pharmacol Sin 25:469-73. 2004
    ..To observe the oral anti-platelet efficacy and the potential action mechanism of polyaspartoyl L-arginine (PDR), a new L-arginine rich compound...
  71. ncbi Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism
    Alexandre Ghuysen
    Hemodynamics Research Laboratory, University of Liege, Belgium
    J Pharmacol Exp Ther 310:964-72. 2004
    ..We conclude that in this animal model of acute pulmonary embolism, infusion of BM-573 reduced pulmonary vasoconstriction. As a result, right ventricular-vascular coupling values were maintained at a maximal efficiency level...
  72. ncbi Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers
    Joanne van Ryn
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Str 65, 88397 Biberach, Germany
    J Clin Pharmacol 44:777-84. 2004
    ....
  73. ncbi Terms and conditions: semantic complexity and aspirin resistance
    Charles H Hennekens
    Department of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Miami, USA
    Circulation 110:1706-8. 2004
  74. ncbi Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Leszek Markuszewski
    Department of Interventional Cardiology, Cardiodiabetology and Cardiac Rehabilitation, Medical University of Lodz, University Hospital No 2, Lodz, Poland
    Basic Clin Pharmacol Toxicol 98:503-9. 2006
    ..Dyslipidaemia and chronic inflammatory states may promote suboptimal acetylsalicylic acid response in coronary artery disease patients...
  75. pmc Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization
    M C Chang
    Biomedical Science Team, Chang Gung Institute of Technology, Taoyuan, Taiwan
    Br J Pharmacol 152:73-82. 2007
    ..Betel leaf (PBL) is consumed by 200-600 million betel quid chewers in the world. Hydroxychavicol (HC), a betel leaf component, was tested for its antiplatelet effect...
  76. ncbi Effects of isradipine on platelet function in hypertension at rest and during exercise
    P Fitscha
    Department of Internal Medicine II, Policlinic, Vienna, Austria
    Am J Hypertens 4:178S-180S. 1991
    ..Systolic and diastolic blood pressures, platelet aggregation in response to adenosine diphosphate (ADP), serum thromboxane B2, and beta-thromboglobulin levels were significantly decreased (P less than ...
  77. ncbi Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 115:3156-64. 2007
    ..Our primary aim was to determine the degree of platelet aspirin responsiveness in patients, as measured by commonly used methods, and to study the relation of aspirin dose to platelet inhibition...
  78. ncbi Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin
    Anetta Undas
    Thromb Haemost 97:1056-8. 2007
  79. doi Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy
    Sasidhar Guthikonda
    Methodist DeBakey Heart Center, 6565 Fannin, F1090, Houston, TX 77030, USA
    Thromb Haemost 100:83-9. 2008
    ..04). In conclusion, platelets in AR subjects demonstrate increased basal sensitivity to submaximal stimulation, which could predict responses to antiplatelet therapy...
  80. ncbi Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings
    Marilena Crescente
    Thromb Haemost 97:1054-6. 2007
  81. ncbi Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism
    Roger Kranzhofer
    Division of Cardiology, University of Heidelberg, Heidelberg, Germany
    Platelets 17:163-9. 2006
    ..However, a correlation exists to elevated eicosanoids generated by oxidative stress indicating COX-1-independent pathways for the generation of platelet activating molecules represent a potential cause for AR...
  82. ncbi Variable platelet response to aspirin in patients with ischemic stroke
    Thomas Hohlfeld
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Deutschland
    Cerebrovasc Dis 24:43-50. 2007
    ..It is not clear whether all of these patients with ischemic stroke respond normally to ASA or are hyporesponsive as assessed by inhibition of aggregation and thromboxane (TX) synthesis...
  83. ncbi Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension
    Francisco X Eizayaga
    Universidad Maimónides, Buenos Aires, Argentina
    World J Gastroenterol 13:5065-70. 2007
    ....
  84. ncbi Differences in the influence of the interaction between acetylsalicylic acid and salicylic acid on platelet function in whole blood and isolated platelets: influence of neutrophils
    J A Gonzalez-Correa
    Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, Campus de Teatinos s n, 29071 Malaga, Spain
    Pharmacol Res 56:168-74. 2007
    ..The variables recorded were maximum platelet aggregation intensity, thromboxane B2 (TxB2) production, and nitric oxide (NO) production (N=10 different samples in each type of experiment)...
  85. ncbi Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C
    D M Skovronsky
    Center for Experimental Therapeutics and The Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 276:17036-43. 2001
    ..By contrast, Abeta release may represent secretion of preformed peptide and is totally independent of both COX and PKC activity...
  86. ncbi The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study
    Joseph DiChiara
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Diabetes 56:3014-9. 2007
    ..Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients...
  87. ncbi Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits
    Pancras C Wong
    Discovery Biology, Bristol Myers Squibb Company, Pennington, New Jersey 08534, USA
    J Cardiovasc Pharmacol 49:316-24. 2007
    ..Moreover, modified IPA and P2Y12 receptor occupancy appear to better predict the magnitude of clopidogrel's efficacy compared with standard IPA, which may be a better predictor of BT...
  88. ncbi Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis
    D Pratico
    Center for Experimental Therapeutics, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Blood 96:3823-6. 2000
    ..Assessment of their generation in these models may afford the basis for future studies on the functional role of these eicosanoids in the evolution and progression of atherosclerosis. (Blood. 2000;96:3823-3826)..
  89. ncbi Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1
    Nauder Faraday
    Department of Anesthesiology Critical Care Medicine, Division of Cardiac Surgical Intensive Care, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Circulation 115:2490-6. 2007
    ..Genetic variation is a proposed but unproved mechanism for insufficient ASA responsiveness...
  90. pmc Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone
    J A Mitchell
    Department of Applied Pharmacology, National Heart and Lung Institute, London
    Br J Pharmacol 113:1008-14. 1994
    ..by the conversion of either endogenous or exogenous arachidonic acid to four metabolites, PGE2, PGF2 alpha, thromboxane B2 or 6-oxo PGF1 alpha measured by radioimmunoassay...
  91. ncbi Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats
    Wei Guo Dong
    Department of Gastroenterology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, Hubei Province, China
    World J Gastroenterol 9:2533-8. 2003
    ..To investigate the ameliorative effects of sodium ferulate (SF) on acetic acid-induced colitis and their mechanisms in rats...
  92. pmc Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture
    D Bishop Bailey
    Department of Applied Pharmacology, National Heart and Lung Institute, Imperial College of Science and Technology, London
    Br J Pharmacol 121:125-33. 1997
    ..system, we have determined the profile of COX (6-keto prostaglandin F1 alpha (6-keto PGF1 alpha), PGE2, thromboxane B2 (TXB2) and NOS (nitrite and nitrate) metabolites released over a period of 10 days from segments of rat aorta...
  93. pmc Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
    D Riendeau
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Br J Pharmacol 121:105-17. 1997
    ..The large increase in selectivity of DFU over indomethacin was also observed in COX-1 mediated production of thromboxane B2 (TXB2) by Ca2+ ionophore-challenged human platelets (IC50 > 50 microM and 4.1 +/- 1.7 nM, respectively). 3...
  94. ncbi Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications
    Jan J Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 32:174-207. 2006
    ..beta-thromboglobulin (beta-TG), platelet factor 4 (PF4), and thrombomodulin (TM) levels, and increased urinary thromboxane B2 (TXB2) excretion, indicating platelet-mediated thrombotic processes...
  95. ncbi Prostaglandin H2 as an endothelium-derived contracting factor modulates endothelin-1-induced contraction
    H Asano
    Department of Internal Medicine II, Nagoya University School of Medicine, Japan
    J Hypertens 12:383-90. 1994
    ..To investigate the possible involvement of prostaglandin H2, an endothelium-derived contracting factor in the rat aorta, in the development of the contraction induced by endothelin-1...
  96. pmc Leukotriene D4 receptors are not negatively coupled to adenylyl cyclase in guinea-pig lung parenchyma
    M A Giembycz
    Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London
    Br J Pharmacol 108:824-32. 1993
    ..with LTD4 (200 nM; EC100 for tension generation) stimulated a 150 and 70 fold increase in the elaboration of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) respectively, relative to that generated ..
  97. ncbi Studies of thromboxane B2, platelet factor 4, and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb-IIIa, and storage granules
    H J Weiss
    Department of Medicine Division of Hematology Oncology, St Luke s Roosevelt Hospital Center, New York, NY 10019
    Blood 82:481-90. 1993
    The blood volumes and concentrations of thromboxane B2 (TxB2), platelet factor 4 (PF4), and fibrinopeptide A (FPA) were measured every 30 seconds in bleeding-time blood in normal subjects and in patients with idiopathic thrombocytopenic ..
  98. pmc Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane
    A Maassen VanDenBrink
    Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, The Netherlands
    Br J Pharmacol 119:855-62. 1996
    ..endothelin-1, but significantly reduced TxA2 production in coronary artery segments as judged by a decrease in thromboxane B2 (TxB2) from 4.77 +/- 0.98 to 1.38 +/- 0.36 ng g-1 2 h-1. 5...
  99. ncbi Intracoronary C5a induces myocardial ischemia by mechanisms independent of the neutrophil: leukocyte filters desensitize the myocardium to C5a
    R L Engler
    Department of Medicine and Pathology, Veterans Administration Medical Center, San Diego, California 92161
    FASEB J 5:2983-91. 1991
    ..blood flow, myocardial contractile function (sonomicrometry), arterial/coronary venous blood PMN count, and thromboxane B2 (TxB2) levels were performed...
  100. ncbi Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts
    J J Michiels
    Hemostasis, Thrombosis and Vascular Research, Department of Hematology, University Hospital, Antwerp, Belgium
    Pathol Biol (Paris) 51:167-75. 2003
    ..higher levels of platelet activation markers beta-thromboglobulin, thrombomoduline and increased urinary thromboxane B2 excretion in thrombocythemia patients suffering from erythromelalgia...
  101. ncbi Effect of short-term enteral feeding with eicosapentaenoic and gamma-linolenic acids on alveolar macrophage eicosanoid synthesis and bactericidal function in rats
    J D Palombo
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Crit Care Med 27:1908-15. 1999
    ....

Research Grants63

  1. CARDIOPULMONARY FAILURE FOLLOWING SHOCK AND TRAUMA
    HERBERT HECHTMAN; Fiscal Year: 1990
    ..1 HC1 into a segmental bronchus. Leukotriene B4 and thromboxane B2 levels and neutrophil counts in bronchoalveolar lavage returns of the aspirated segment and plasma will be ..
  2. POST-PROTAMINE COMPLEMENT ACTIVATION IN CARDIAC SURGERY
    Kaushikkumar Shastri; Fiscal Year: 1993
    ..prior to bypass, 3. before protamine, 4. 10 minutes after protamine. Leukotriene B4 and thromboxane B2 will be determined on samples drawn from pulmonary artery and radial artery lines to represent pre-and post-..
  3. Aspirin and Simvastatin--Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2006
    ..We hypothesize that aspirin will decrease soluble P-selectin, serum thromboxane B2, and /Mhromboglobulin in patients with PAH compared to placebo over six months...
  4. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2009
    ..We hypothesize that aspirin will decrease soluble P-selectin, serum thromboxane B2, and /Mhromboglobulin in patients with PAH compared to placebo over six months...
  5. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2007
    ..We hypothesize that aspirin will decrease soluble P-selectin, serum thromboxane B2, and /Mhromboglobulin in patients with PAH compared to placebo over six months...
  6. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2009
    ..We hypothesize that aspirin will decrease soluble P-selectin, serum thromboxane B2, and /Mhromboglobulin in patients with PAH compared to placebo over six months...
  7. NERVE BLOOD FLOW IN NORMAL AND ISCHEMIC PERIPHERAL NERVE
    Phillip Low; Fiscal Year: 1991
    ..and superoxide dismutase (SOD) as indices of OFR damage and the biosynthesis by nerve in situ and in vitro of thromboxane B2 and 6-keto-PFG1 alpha will be used as indices of nerve eiscosanoids and nerve catecholamines will be measured...
  8. NERVE BLOOD FLOW IN NORMAL AND ISCHEMIC PERIPHERAL NERVE
    Phillip Low; Fiscal Year: 1993
    ..and superoxide dismutase (SOD) as indices of OFR damage and the biosynthesis by nerve in situ and in vitro of thromboxane B2 and 6-keto-PFG1 alpha will be used as indices of nerve eiscosanoids and nerve catecholamines will be measured...
  9. NERVE BLOOD FLOW IN NORMAL AND ISCHEMIC PERIPHERAL NERVE
    Phillip Low; Fiscal Year: 1992
    ..and superoxide dismutase (SOD) as indices of OFR damage and the biosynthesis by nerve in situ and in vitro of thromboxane B2 and 6-keto-PFG1 alpha will be used as indices of nerve eiscosanoids and nerve catecholamines will be measured...
  10. NERVE BLOOD FLOW IN NORMAL AND ISCHEMIC PERIPHERAL NERVE
    Phillip Low; Fiscal Year: 1990
    ..and superoxide dismutase (SOD) as indices of OFR damage and the biosynthesis by nerve in situ and in vitro of thromboxane B2 and 6-keto-PFG1 alpha will be used as indices of nerve eiscosanoids and nerve catecholamines will be measured...
  11. ER beta selective agonist coronary protection-menopause
    R Hermsmeyer; Fiscal Year: 2004
    ..In addition, C-Reactive Protein (CRP) in serum and thromboxane B2 in urine will be used as adverse indicators...
  12. ER beta selective agonist coronary protection-menopause
    R Hermsmeyer; Fiscal Year: 2005
    ..In addition, C-Reactive Protein (CRP) in serum and thromboxane B2 in urine will be used as adverse indicators...
  13. PULMONARY VASCULAR ACTIONS OF THROMBOXANE A2
    MARTIN OGLETREE; Fiscal Year: 1980
    ..Measurements of lymph thromboxane B2 concentrations will allow evaluation of the in vivo effectiveness of thromboxane synthetase inhibitors with ..
  14. THE PHARMACOLOGY OF ASPIRIN
    John Oates; Fiscal Year: 2006
    ..High levels of excretion of the thromboxane metabolite, 11 -dehydro-thromboxane B2 (TxM), have been associated with an increased risk of coronary events...
  15. IN VIVO INVESTIGATIONS USING MICRODIALYSIS SAMPLING
    Craig Lunte; Fiscal Year: 2009
    ..First, the COX products prostaglandin E2 and thromboxane B2 and the LOX products the hydroxyeicosatetraenoic acids, 5-HETE and 15-HETE, and leukotriene B4 will be ..
  16. IN VIVO INVESTIGATIONS USING MICRODIALYSIS SAMPLING
    Craig E Lunte; Fiscal Year: 2010
    ..First, the COX products prostaglandin E2 and thromboxane B2 and the LOX products the hydroxyeicosatetraenoic acids, 5-HETE and 15-HETE, and leukotriene B4 will be ..
  17. ARACHIDONIC ACID METABOLITES IN DIABETES MELLITUS
    Lloyd Axelrod; Fiscal Year: 1980
    ..Thromboxane A2 (analyzed as thromboxane B2), prostacyclin (analyzed as 6-keto-PGF1 alpha and 6,15-diketo-PGF1 alpha), PGE2 (analyzed as 13,14-dihydro-..
  18. Mechanisms for Adverse Renal Effects from Lead Exposure
    Virginia Weaver; Fiscal Year: 2006
    ..6 hemodynamic biomarkers (urinary prostaglandin E2, prostaglandin F2 alpha, 6-keto-prostaglandin F1 alpha, thromboxane B2, and total nitrites/nitrates and plasma renin level), and whether these biomarkers are associated with adverse ..
  19. DIABETIC VASCULAR ENDOTHELIUM & ADRENERGIC NERVES
    Richard Cohen; Fiscal Year: 1990
    ..Prostanoids including 6-keto-PGF1a, thromboxane B2, PGF2a, PGE2, and 15-HETE will be measured by radioimmunoassay, and radiochromatography will be used to ..
  20. CHARACTERIZATION OF CYCLOSPORINE NEPHROTOXICITY
    Richard Wait; Fiscal Year: 1990
    ..sodium and potassium excretion, excretion rates of n-acetyl-B-glucosaminidase, PGE2, 6-ketoPGF2alpha, thromboxane B2 and plasma renin...
  21. EFFECTS OF PROSTAGLANDINS ON MYOMETRIAL METABOLISM
    CLARISSA BEATTY; Fiscal Year: 1980
    ..e., PGE2, PGD2, PGF2 alpha, PGI2, and thromboxane B2. Levels of enzyme activity will be measured in samples of taenia coli to determine if the changes seen during ..
  22. MECHANISM OF PROSTHETIC ARTERIAL GRAFT FAILURE
    Frank Logerfo; Fiscal Year: 1992
    ..count, mean platelet volume, platelet aggregation and degranulation studies, platelet survival studies, thromboxane B2 release, and transforming growth B1, 2) white blood cells; wbc count, differential, 3) complete blood count; ..
  23. STATISTICAL GENETICS OF PDGF RELATED PHENOTYPES
    MICHAEL MAHANEY; Fiscal Year: 1999
    ..These traits, including platelet number and volume, serum platelet activating factor (PAF), plasma thromboxane B2, serum insulin- like growth factor-1 (IGF-1), and total and high density lipoprotein cholesterol, will be ..
  24. DENTAL ATHEROSCLEROSIS RISK IN COMMUNITIES
    James Beck; Fiscal Year: 1999
    ..provide a biological burden of endotoxin (LPS, lipopolysaccharide) and inflammatory cytokines (especially thromboxane B2 [TxB2], interleukin-1 beta [Il-1b], prostaglandin E2 [PGE2] and tumor necrosis factor alpha [TNFa]) which ..
  25. STATISTICAL GENETICS OF PDGF RELATED PHENOTYPES
    MICHAEL MAHANEY; Fiscal Year: 2000
    ..These traits, including platelet number and volume, serum platelet activating factor (PAF), plasma thromboxane B2, serum insulin- like growth factor-1 (IGF-1), and total and high density lipoprotein cholesterol, will be ..
  26. DENTAL ATHEROSCLEROSIS RISK IN COMMUNITIES
    James Beck; Fiscal Year: 1999
    ..provide a biological burden of endotoxin (LPS, lipopolysaccharide) and inflammatory cytokines (especially thromboxane B2 [TxB2], interleukin-1 beta [Il-1b], prostaglandin E2 [PGE2] and tumor necrosis factor alpha [TNFa]) which ..
  27. REGULATION OF POLYMORPHONUCLEAR LEUKOCYTE FUNCTION
    Peter Reed; Fiscal Year: 1980
    ..In pursuit of this goal we will: quantitate production of primary prostaglandins, thromboxane B2 and their metabolites and hydroxylated fatty acids; measure cyanide-resistant oxygen utilization, O2, and H2O2 ..
  28. COLON CANCER PREVENTION PROGRAM PROJECT
    David Alberts; Fiscal Year: 1990
    ..markers of cancer risk will be assessed serially, including measurement of PGE2, 6-KETO- PGF1alpha and thromboxane B2 levels and [3H]-thymidine labeling index in crypt organ culture. ...
  29. ASPIRIN/FOLATE PREVENTION OF LARGE BOWEL POLYPS
    John Baron; Fiscal Year: 1999
    ..We also propose to measure urinary thromboxane B2, and red blood cell and serum folate near the time of study completion...
  30. PLATELET REACTIVITY AND DISORDERS OF PLATELET FUNCTION
    Harvey Weiss; Fiscal Year: 1990
    ..hemostasis, by obtaining, in a wide variety of patients with prolonged bleeding times and/or known platelet dysfunction, time-course studies on blood volume, thromboxane B2, platelet factor 4 and fibrinopeptide A in bleeding time blood.
  31. SEQUENCE OF EVENTS IN STIMULATED BLOOD PLATELETS
    HOWARD BENSUSAN; Fiscal Year: 1980
    ..have shown that when cold-poised platelets are rewarmed, there is no evidence of arachidonate formation or thromboxane B2 synthesis...
  32. CAD MECHANISMS IN HIGH RISK FAMILIES--RACIAL DI FFERENCE
    Lewis Becker; Fiscal Year: 1992
    ..function will be assessed by spontaneous in-vitro aggregation, activated IIa/IIIb receptor density, and serum thromboxane B2 concentration...
  33. CARDIOPULMONARY FAILURE FOLLOWING SHOCK AND TRAUMA
    HERBERT HECHTMAN; Fiscal Year: 1980
    ..This bioassay requires only 0.1 ml plasma. The importance of other negative inotropes, such as thromboxane B2, will be tested by radioimmunoassay of the plasma of PEEP treated subjects...
  34. SYSTEMIC EFFECTS OF PERIODONTITIS
    James Beck; Fiscal Year: 2002
    ..Sanguis. Gingival crevicular fluid will be collected for the quantitation of Prostaglandin E2 (PGE2) thromboxane B2 (TxB2), Interleukin-1B (IL-1B) and tumors necrosis factor a (TNFa)...
  35. SYSTEMIC EFFECTS OF PERIODONTITIS
    James Beck; Fiscal Year: 2001
    ..Sanguis. Gingival crevicular fluid will be collected for the quantitation of Prostaglandin E2 (PGE2) thromboxane B2 (TxB2), Interleukin-1B (IL-1B) and tumors necrosis factor a (TNFa)...
  36. SYSTEMIC EFFECTS OF PERIODONTITIS
    James Beck; Fiscal Year: 2000
    ..Sanguis. Gingival crevicular fluid will be collected for the quantitation of Prostaglandin E2 (PGE2) thromboxane B2 (TxB2), Interleukin-1B (IL-1B) and tumors necrosis factor a (TNFa)...
  37. NIH-GMS-SHARED GC/MS-COMPUTER INSTRUMENTATION
    Brian Sweetman; Fiscal Year: 1980
    ..of indomethacin, chemical studies of vancomycin-ristocetin antibiotics, metabolic fate and quantitation of thromboxane B2 and prostacyclin in man, identification of metabolites of arachidonic acid in mast cells, and humoral effects ..
  38. STRUCTURE/FUNCTION STUDY OF A PROSTAGLANDIN TRANSPORTER
    BRENDA CHAN; Fiscal Year: 2000
    ..PGT", a PG transporter expressed strongly in the renal papilla, transports PGE2, PGF2alpha, and thromboxane B2, and appears to mediate PG metabolic clearance...
  39. STRUCTURE/FUNCTION STUDY OF A PROSTAGLANDIN TRANSPORTER
    BRENDA CHAN; Fiscal Year: 1999
    ..PGT", a PG transporter expressed strongly in the renal papilla, transports PGE2, PGF2alpha, and thromboxane B2, and appears to mediate PG metabolic clearance...
  40. INFLAMMATION: CORRELATES AND PROGNOSIS IN FRAMINGHAM
    Emelia Benjamin; Fiscal Year: 2001
    ..monocyte chemotactic protein-1, tumor necrosis factor-alpha) and oxidative stress markers (8-epi-PGF 2alpha, thromboxane B2). The specific aims of this proposal are to: 1...
  41. INFLAMMATION: CORRELATES AND PROGNOSIS IN FRAMINGHAM
    Emelia Benjamin; Fiscal Year: 2003
    ..monocyte chemotactic protein-1, tumor necrosis factor-alpha) and oxidative stress markers (8-epi-PGF 2alpha, thromboxane B2). The specific aims of this proposal are to: 1...
  42. INFLAMMATION: CORRELATES AND PROGNOSIS IN FRAMINGHAM
    Emelia Benjamin; Fiscal Year: 2000
    ..monocyte chemotactic protein-1, tumor necrosis factor-alpha) and oxidative stress markers (8-epi-PGF 2alpha, thromboxane B2). The specific aims of this proposal are to: 1...
  43. INFLAMMATION: CORRELATES AND PROGNOSIS IN FRAMINGHAM
    Emelia Benjamin; Fiscal Year: 2002
    ..monocyte chemotactic protein-1, tumor necrosis factor-alpha) and oxidative stress markers (8-epi-PGF 2alpha, thromboxane B2). The specific aims of this proposal are to: 1...
  44. HYPERGEN
    John Eckfeldt; Fiscal Year: 1999
    ..anticipated 1,000 "special" tests include: U kallikrein, U 6-OH-cortisol, U aldosterone, U prostaglandin E2, U thromboxane B2, U catecholamines, P renin activity, P angiotensinogen, P endothelin, and P atrial natriuretic peptide...
  45. Strategies for Efficient Routes to Bioactive Substances
    Steven Burke; Fiscal Year: 2005
    ..Didemniserinolipid B, containing the 6,8-dioxabicyclo[3.2.1]octane skeleton common in bioactive agents; . Thromboxane B2-(TXBz)...
  46. Strategies for Efficient Routes to Bioactive Substances
    Steven Burke; Fiscal Year: 2003
    ..Didemniserinolipid B, containing the 6,8-dioxabicyclo[3.2.1]octane skeleton common in bioactive agents; . Thromboxane B2-(TXBz)...
  47. Strategies for Efficient Routes to Bioactive Substances
    Steven Burke; Fiscal Year: 2006
    ..Didemniserinolipid B, containing the 6,8-dioxabicyclo[3.2.1]octane skeleton common in bioactive agents; . Thromboxane B2-(TXBz)...
  48. Strategies for Efficient Routes to Bioactive Substances
    Steven Burke; Fiscal Year: 2004
    ..Didemniserinolipid B, containing the 6,8-dioxabicyclo[3.2.1]octane skeleton common in bioactive agents; . Thromboxane B2-(TXBz)...